Clinical Trial: Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC

U.S., Dec. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07267806) titled 'Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC' on Nov. 25.

Brief Summary: This is a multi-center randomized phase III clinical study of first-line Camrelizumab and Apatinib with or without intravenous FOLFOX Chemotherapy for Advanced Hepatocellular Carcinoma (HCC).

Study Start Date: Oct. 31

Study Type: INTERVENTIONAL

Condition: Hepato Cellular Carcinoma (HCC) Chemotherapy Effect

Intervention: DRUG: Infusional mFOLFOX7 plus Camrelizumab and apatinib

Oxaliplatin 85mg/m2 IV on Days 1 of a 21 day cycle Fluorouracil 5-FU continuous infusion: 400mg/m2 on Dand then 2400mg/m2 for 46h of each 21 day cyc...